Research News for 2011
-
Avastin Plus Taxol May Help Treat Metastatic, Triple-Negative Disease
Some women diagnosed with triple-negative metastatic breast cancer benefit from a combination of Avastin and Taxol.
-
Adding Iniparib to Second, Third Chemo Regimen May Help Treat Metastatic, Triple-Negative Disease
A new analysis suggests that women diagnosed with triple-negative metastatic breast cancer that was previously treated benefited from adding iniparib to the second or third chemotherapy regimen.
-
Nexavar Offers No Benefits in Treating Advanced-Stage Disease
A small, early study suggests that Nexavar offers no benefits for advanced-stage breast cancer treatment.
-
Zometa Seems to Reduce Recurrence Risk of Early-Stage Breast Cancer
A study suggests that Zometa after surgery may reduce the risk of recurrence and improve overall survival in postmenopausal women diagnosed with early-stage breast cancer.
-
Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission
Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.
-
Giving Chemo and Radiation Therapy at Same Time Offers Same Benefits as Sequential Timing
In a study of women who'd been diagnosed with early breast cancer, local recurrence happened 35% less often in those who were treated with chemotherapy and radiation at the same time rather than sequentially (one after the other).
-
Experimental T-DM1 May Help Treat Advanced-Stage, HER2-Positive Disease
In a preliminary study, women with HER2-positive locally advanced or metastatic breast cancer treated with the targeted therapy T-DM1 lived longer without the cancer showing signs of progression compared to similar women who received a standard treatment combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel).
-
Afinitor Added to Aromasin Slows Advanced-Stage Breast Cancer Growth
A study showed that postmenopausal women with advanced breast cancer who took Afinitor (chemical name: everolimus) with the aromatase inhibitor Aromasin (chemical name: exemestane) appeared to have longer progression-free survival compared to women taking Aromasin with a placebo.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Worldwide Risk of Being Diagnosed with Breast Cancer Increasing
A new analysis of global trends over a 30-year span shows that breast and cervical cancers are on the rise.
